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Abstract
Objective To assess the effect of targeting intensive glycaemic control
versus conventional glycaemic control on all cause mortality and
cardiovascular mortality, non-fatal myocardial infarction, microvascular
complications, and severe hypoglycaemia in patients with type 2
diabetes.
Design Systematic review with meta-analyses and trial sequential
analyses of randomised trials.
Data sources Cochrane Library, Medline, Embase, Science Citation
Index Expanded, LILACS, and CINAHL to December 2010; hand search
of reference lists and conference proceedings; contacts with authors,
relevant pharmaceutical companies, and the US Food and Drug
Administration.
Study selection Randomised clinical trials comparing targeted intensive
glycaemic control with conventional glycaemic control in patients with
type 2 diabetes. Published and unpublished trials in all languages were
included, irrespective of predefined outcomes.
Data extraction Two reviewers independently assessed studies for
inclusion and extracted data related to study methods, interventions,
outcomes, risk of bias, and adverse events. Risk ratios with 95%
confidence intervals were estimated with fixed and random effects
models.
Results Fourteen clinical trials that randomised 28 614 participants with
type 2 diabetes (15 269 to intensive control and 13 345 to conventional
control) were included. Intensive glycaemic control did not significantly
affect the relative risks of all cause (1.02, 95% confidence interval 0.91
to 1.13; 28 359 participants, 12 trials) or cardiovascular mortality (1.11,
0.92 to 1.35; 28 359 participants, 12 trials). Trial sequential analyses
rejected a relative risk reduction above 10% for all cause mortality and
showed insufficient data on cardiovascular mortality. The risk of non-fatal
myocardial infarction may be reduced (relative risk 0.85, 0.76 to 0.95;
P=0.004; 28 111 participants, 8 trials), but this finding was not confirmed
in trial sequential analysis. Intensive glycaemic control showed a
reduction of the relative risks for the composite microvascular outcome
(0.88, 0.79 to 0.97; P=0.01; 25 600 participants, 3 trials) and retinopathy
(0.80, 0.67 to 0.94; P=0.009; 10 793 participants, 7 trials), but trial
sequential analyses showed that sufficient evidence had not yet been
reached. The estimate of an effect on the risk of nephropathy (relative
risk 0.83, 0.64 to 1.06; 27 769 participants, 8 trials) was not statistically
significant. The risk of severe hypoglycaemia was significantly increased
when intensive glycaemic control was targeted (relative risk 2.39, 1.71
to 3.34; 27 844 participants, 9 trials); trial sequential analysis supported
a 30% increased relative risk of severe hypoglycaemia.
Conclusion Intensive glycaemic control does not seem to reduce all
cause mortality in patients with type 2 diabetes. Data available from
randomised clinical trials remain insufficient to prove or refute a relative
risk reduction for cardiovascular mortality, non-fatal myocardial infarction,
composite microvascular complications, or retinopathy at a magnitude
of 10%. Intensive glycaemic control increases the relative risk of severe
hypoglycaemia by 30%.
Introduction
Observationalstudiessuggestanassociationbetweentheextent
of hyperglycaemia and the risk of death and of macrovascular
and microvascular disease in patients with type 2 diabetes.
1-3
Three recent randomised clinical trials in patients with type 2
diabetes were not able to detect (or reject the possibility of)
reduced cardiovascular disease or mortality with intensive
comparedwithconventionalglycaemiccontrol.
4-6Worriesarose
as the results from the Action to Control Cardiovascular Risk
inDiabetes(ACCORD)trialin2008showedincreasedallcause
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Research
RESEARCHmortalityandcardiovascularmortalityintheintensivetreatment
group compared with conventional treatment.
4 The increased
mortality led to early termination of the ACCORD trial.
4 On
the other hand, randomised clinical trials have indicated a
beneficial effect on microvascular complications of intensive
versus conventional glycaemic control in patients with type 2
diabetes. However, inconsistencies exist among the trials with
respect to which type of microvascular complications are
preventedandthemagnitudeoftheeffectofintensiveglycaemic
control.
5 7 8 The price of intensive glycaemic control may be an
increasedriskofhypoglycaemia.Achievingintensiveglycaemic
controlinpatientswithtype2diabetesrequiresenormouseffort
fromthepatientaswellasresourcesfromthehealthcaresystem,
particularly compared with the well documented beneficial
effects of lipid and blood pressure lowering treatment.
9
The definition of intensive glycaemic control varies among
trials and guidelines. The ACCORD trial and the Veterans
Affairs Diabetes Trial (VADT) used a target of glycated
haemoglobin A1c (HbA1c) below 6.0% for intensive glycaemic
control compared with a target of HbA1c below 6.5% in the
Action in Diabetes and Vascular Disease—Preterax and
Diamicron Modified Release Controlled Evaluation
(ADVANCE) trial. The results from these trials have created a
debate about the optimal choice of glycaemic target. The
American Diabetes Association recommends an HbA1c level of
lessthan7.0%asthestandardglycaemictreatmentgoal,whereas
the International Diabetes Federation recommends a level of
less than 6.5%.
10-12
In our published protocol, we predefined inclusion of all trials
comparing patients treated to a specific target for intensive
glycaemic control with patients treated to a conventional but
higher glycaemic target.
13 The difference in treatment strategy
betweenthegroupswasclearlydefinedeitherasvaluesofHbA1c
or as intensifying glycaemic control. The intensive glycaemic
targetsvariedacrossthetrials,butthetrialscomparedtheresults
of trying to achieve a distinct lower target with those of aiming
for a higher one. We believe that the existence of a “gold
threshold” target remains to be established and that the
hypothesis so far has been that targeting/lowering the HbA1c
may have a beneficial effect along the entire scale of
measurements of HbA1c unless hypoglycaemia is reached. In
this sense, we have included all trials comparing an intensified
glycaemic target with a more “relaxed” glycaemic target, often
reflecting usual clinical practice for a given place and time.
Thissystematicreviewreanalysescurrentevidenceoftheeffect
of targeting intensive glycaemic control on all cause mortality,
cardiovascular mortality, cardiovascular disease, and
microvascular disease in patients with type 2 diabetes. We
consider the effects of intensive glycaemic control irrespective
of differences among trials in individual targets or achieved
glycaemic control.
13
As well as assessing the effect of intensive glycaemic control
on the outcomes reported in this systematic review (all cause
mortality, cardiovascular mortality, non-fatal myocardial
infarction,compositemicrovascularcomplications,retinopathy,
andnephropathy),weassessedmacrovascularcomplicationsas
a composite outcome, non-fatal stroke, peripheral and cardiac
revascularisation, retinal photocoagulation, end stage renal
disease, congestive heart failure, adverse events, the cost of the
intervention, and quality of life. The results for these
supplemental outcomes are published elsewhere.
14
Methods
This review follows the recommendations of the Cochrane
Collaboration.
15ItisbasedonourpublishedCochraneprotocol.
13
We included all randomised trials that compared the targeting
of intensive glycaemic versus conventional glycaemic control
inpatientswithtype2diabetes.
13 14Weanalysedtrialsaccording
to the setting of the intensive glycaemic intervention. We
analysed trials of targeting intensive glycaemic control in
patients without acute events at entry or without concomitant
treatments targeting other cardiovascular risk factors as “trials
exclusively dealing with glycaemic control in usual care
setting.”
13 The data in the review reported here are from this
groupoftrials,representing28614(95%)of29986participants
included in our review.
13 14 We excluded three trials assessing
multimodal interventions,
16-18 as well as three trials assessing
intensive glycaemic control as part of an acute intervention.
19-21
For the vast majority of estimated effects of intervention, these
exclusions did not cause noticeable changes.
13
We analysed trials of targeting intensive glycaemic control as
part of an acute intervention and trials with multimodal
interventionsseparately.
13 14Wealsodidanoverallmeta-analysis
combiningdatafromallincludedtrialsirrespectiveofthesetting
in which intensive glycaemic control was applied.
13 14 We refer
only to data from the analyses of trials exclusively dealing with
glycaemic control in usual care setting in this paper, but the
Cochrane version gives a full presentation.
14
Search strategy
We did a search in the Cochrane Library, Medline, Embase,
Science Citation Index Expanded, LILACS, and CINAHL in
December 2010 for randomised clinical trials of targeting
intensive glycaemic control versus targeting conventional
glycaemiccontrolinpatientswithtype2diabetes.Webappendix
1 describes the search terms and strategies for each database.
We also searched abstracts presented at the American Diabetes
AssociationandEuropeanAssociationfortheStudyofDiabetes
congresses. We contacted relevant drug companies and the US
Food and Drug Administration for unpublished randomised
trials relevant to our review. We searched reference lists of
included trials and (systematic) reviews, meta-analyses, and
health technology assessment reports. We did internet searches
for all trials to find additional information about the included
trials. We contacted authors for information about additional
trials.
Study selection
Twoauthors(BHandAV,CG,CH,SSL,orTA)independently
screened titles and abstracts according to the inclusion criteria.
We included a trial if it was a randomised clinical trial,
comparedtargetingintensiveglycaemiccontrolversustargeting
conventional glycaemic control, and was done in patients with
type 2 diabetes. We included trials irrespective of duration,
language, publication status, or predefined outcomes.
Data extraction and risk of bias assessment
Two authors (BH and CH or TA) independently extracted
information from each included trial by using standard data
extraction forms and assessed the risk of bias as advised in the
Cochrane Handbook of Systematic Reviews of Interventions.
15
We assessed the following risk of bias domains: sequence
generation, concealment of allocation, blinding, incomplete
outcome data, selective outcome reporting, and other sources
of bias.
15 We classified each domain as adequate, unclear, or
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RESEARCHinadequate. Web appendix 2 gives details. Discrepancies
betweenauthors’assessmentswereresolvedbyinvolvementof
a third author (JW). Translators extracted data from all relevant
non-English articles.
We extracted data on several baseline characteristics of the
participants (such as age, duration of disease, HbA1c) and
outcomes. The predefined outcomes reported in this review are
all cause mortality, cardiovascular mortality, non-fatal
myocardial infarction, microvascular disease reported as a
composite outcome, retinopathy, nephropathy, and severe
hypoglycaemia.
13 We sought any relevant missing information
from the original author(s) of the randomised trial.
When we identified more than one publication of an original
trial, we assessed these together to maximise data collection.
In case of substantial disagreements between older and newer
publications, we contacted the authors.
Statistical analysis
We used Review Manager version 5.0.25 for statistical
analysis.
22 We summarised data on all cause mortality,
cardiovascular mortality, non-fatal myocardial infarction, and
severe hypoglycaemia statistically as relative risks with 95%
confidenceintervals.Weusedbotharandomeffectsmodeland
afixedeffectmodel.
23 24Incaseofdiscrepancybetweenthetwo
models,wereportbothresults;otherwise,wereporttherandom
effects model.
WeexaminedheterogeneitywiththeI
2statistic,quantifyingthe
proportion of between trial variance to the sum of the between
trialvarianceandacommonsamplingerror.
25Wegradedvalues
of I
2 between 0% to 40% as “heterogeneity might not be
important,” values between 30% and 60% as “moderate
heterogeneity,” values between 50% and 90% as “substantial
heterogeneity,” and values between 75% and 100% as
“considerable heterogeneity.”
25 When we found heterogeneity,
we attempted to determine potential reasons by examining
characteristics of individual trials.
We did subgroup analyses stratifying trials according to risk of
bias, length of study, diagnostic criteria for type 2 diabetes,
language of publication, and source of funding for all cause
mortality, cardiovascular mortality, and non-fatal myocardial
infarction.
We did trial sequential analyses.
26 27 This is similar to interim
analysesinasingletrial,wheremonitoringboundariesareused
to decide whether a trial could be terminated early when a P
valueissufficientlysmalltoshowtheanticipatedeffect.Because
no reason exists why the standards for a meta-analysis should
be less rigorous than those for a single trial, analogous trial
sequential monitoring boundaries can be applied to
meta-analysis.
28-30 Cumulative meta-analyses of trials are at risk
ofproducingrandomerrorsbecauseofsparsedataandrepetitive
testingofaccumulatingdatawhentherequiredinformationsize
(analogous to the sample size of an optimally powered clinical
trial) has not been met. Trial sequential analysis depends on the
quantificationoftherequiredinformationsize(themeta-analysis
samplesize).Inthiscontext,thesmallertherequiredinformation
size the more lenient the trial sequential monitoring boundaries
are and, accordingly, the more lenient the criteria for statistical
significancewillbe.Wecalculatedaheterogeneity(I²)adjusted
required information size. We did the trial sequential analyses
withanintentiontomaintainanoverall5%riskofatypeIerror,
which is the standard in most meta-analyses and systematic
reviews. On the basis of pre-determined criteria,
13 we initially
calculated the required information size to detect or reject an
intervention effect of a 10% relative risk reduction with a risk
of a type II error of 20% (power of 80%). We chose a 10%
relative risk reduction equivalent to a number needed to treat
of approximately 100 patients, because even this decrease in
mortality is likely to be clinically meaningful. For severe
hypoglycaemia, however, we chose a 30% increase in relative
risk equivalent to a number needed to harm of 50. We also
provide the 95% confidence intervals adjusted for sparse data
and repetitive testing, which we describe as the trial sequential
analysis adjusted 95% confidence intervals. We used TSA
version 0.9 beta (www.ctu.dk/tsa) for these analyses.
Results
Results of the search and trial, participant,
and intervention characteristics
Figure 1⇓ summarises the results of the search. We excluded
42 references after further evaluation. The main reasons for
exclusion were that the trial was not randomised (11
references),
31-41 participants were not patients with type 2
diabetes or we could not separate data on patients with type 2
diabetes (four references),
42-45 or no predefined differences in
glycaemic intervention target existed (16 references).
46-61 In
addition, we excluded trials that assessed intensive glycaemic
control as a part of an acute intervention (five references, three
trials) or had concomitant targeting of several cardiovascular
risk factors in the glycaemic intervention arm (six references,
three trials).
16-21 62-66 Table 1⇓ gives a list of excluded trials.
Weincluded20randomisedtrials,ofwhich14exclusivelydealt
with glycaemic control in the usual care setting in patients
without acute events at entry.
4-8 67-111 Thirteen of the trials were
publishedinEnglishandoneinRussian.
85The14includedtrials
were described in 51 publications. We noted a discrepancy in
the number of participants in two publications of one trial.
83 84
We used baseline data from the publication in the Netherlands
Journal of Medicine.
83
The trials included 28 614 participants, of whom 15 269 were
randomised to intensive glycaemic control and 13 345 to
conventional glycaemic control. Table 2⇓ shows key
characteristics of the included trials, and table 3⇓ shows
characteristics of trials’ participants. The included trials were
mainly done in North America and Europe. The number of
randomised patients in each trial ranged from 20 to 11 140.
5 87
All 14 included trials were randomised clinical trials.
Two of the trials had a factorial design.
4 5 The UK Prospective
Diabetes Study (UKPDS) had a substudy in which some of the
participantswererandomisedtointensivebloodpressurecontrol
versus conventional blood pressure control.
102 The University
Group Diabetes Program (UGDP) randomised participants to
five different treatment regimens.
88 We chose to report the
“insulin variable” group as the intensive group and the “insulin
standard” group as the conventional group.
The Kumamoto trial had a planned length of intervention of six
years.
7 Only two of the included 110 participants changed their
glycaemicinterventionregimenafterthepredefinedintervention
period. The trial therefore continued on the initiative of the
participants. We have reported all outcomes in this analysis
after 10 years of follow-up, except for severe hypoglycaemia
(reported after eight years of follow-up).
95
Ten trials described how the diagnosis of type 2 diabetes was
established (see web appendix 3).
4 6-8 82 83 87 88 92 106 Four trials
didnotdescribehowthediagnosiswasestablished.
5 85 86 94Most
exclusion criteria consisted of liver disease, kidney disease, or
other severe concurrent illnesses.
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RESEARCHThe anti-diabetes interventions used in the trials often included
add-onregimensconsistingofseveraloraldrugs.Ifparticipants
couldnotreachtheglycaemictargetwiththeseregimens,insulin
was started. The usual add-on regimen was identical in the
intensive and conventional intervention groups of the single
trials, except in the ADVANCE trial and the Rational Effective
Multicomponent Therapy in the Struggle Against DiaBetes
Mellitus in Patients With COngestve Heart Failure (REMBO)
trial, in which participants targeting intensive glucose control
were given gliclazide.
5 85 Most trials allowed combination of
oral anti-diabetes interventions and insulin. Two trials allowed
only monotherapy (insulin) in both the intensive intervention
group and conventional intervention group.
7 88
Thetreatmenttargetsforglycaemiccontrolvariedbetweentrials
in both the intensive treatment group and the conventional
treatment group (table 2⇓). The ACCORD trial and the VADT
had the lowest target for HbA1c in the intensive intervention
groups(bothlessthan6%).
4 6Someofthetrialsdidnotpredefine
theglycaemictargetinvaluesofHbA1cbutusedfastingglucose
concentration as a target for treatment.
8 83 86 88 94
Bias risk assessment
Wedividedthetrialsintothosewithalowriskofbiasandthose
with a high risk of bias on the basis of assessment of sequence
generation, concealment of allocation, and blinding according
to the Cochrane Handbook risk of bias tool.
15 When we judged
all three domains to have a low risk of bias, we designated the
trial as having a low risk of bias. Table 4⇓ reports the bias risk
assessments of the included trials. We considered six trials to
have a low risk of bias.
4-6 8 88 92
Clinical outcomes
All cause mortality
Twelve trials provided information on all cause mortality in a
total of 28 359 participants (fig 2⇓). Meta-analysis showed no
significant effect of intensive glycaemic control (relative risk
1.02, 95% confidence interval 0.91 to 1.13; P=0.74; 28 359
participants, 12 trials) compared with conventional glycaemic
control. Heterogeneity was moderate (I
2=30%; P=0.18).
Subgroup analyses of the trials according to risk of bias, length
of study, diagnostic criteria for type 2 diabetes, and source of
funding showed no statistically significant differences between
subgroups(thatis,nosignificantinteraction).Subgroupanalyses
for language of publication could not be done.
Trial sequential analysis showed that only 28 149 of the
heterogeneity adjusted required information size of 46 677
patients were accrued. The cumulative Z curve did not cross
any boundaries for benefit or harm (trial sequential analysis
adjusted 95% confidence interval 0.88 to 1.18) (fig 3⇓).
However,thecumulativeZcurvecrossedthefutilityboundaries,
suggestingthatarelativeriskreductionof10%orgreatercould
be rejected.
Cardiovascular mortality
Twelvetrialsprovidedinformationoncardiovascularmortality
andwereincludedintheanalyses.Webappendix3givesdetails
of the definitions and reporting of cardiovascular mortality in
the trials. The meta-analysis of the 12 trials did not show a
statistically significant effect of the intervention on
cardiovascularmortality(relativerisk1.11,0.92to1.35;P=0.27;
28 359 participants, 12 trials). Figure 4⇓ shows the forest plot
analysisofcardiovascularmortality.Heterogeneitywaspresent
(I
2=46%; P=0.08).
Subgroup analyses of the trials according to risk of bias, length
of study, and source of funding showed no statistically
significant differences between subgroups. Subgroup analyses
for language of publication could not be done. Including only
trials that described the diagnostic criteria for type 2 diabetes
changed the effect estimate to a significant value in favour of
conventionalglycaemiccontrol(relativerisk1.26,1.08to1.46;
P=0.002; 17 093 participants, 9 trials). The test for interaction
showed a statistically significant difference between the two
estimates (P=0.001).
Trial sequential analysis showed that barely 22% of the
heterogeneity adjusted required information size to detect or
reject a 10% relative risk reduction was actually accrued (trial
sequential analysis adjusted 95% confidence interval 0.70 to
1.76). None of the boundaries for benefit, harm, or futility was
crossed, showing too little evidence to allow us to conclude
whether the intervention was beneficial, harmful, or without
any effect on this outcome (fig 5⇓).
Non-fatal myocardial infarction
A total of 1237 non-fatal myocardial infarctions were recorded
in 28 111 participants from eight trials. The details of how the
diagnosis of myocardial infarction was defined varied among
the trials (web appendix 3). The effect estimate showed a
significant benefit of targeting intensive glycaemic control in
a conventional meta-analysis (relative risk 0.85, 0.76 to 0.95;
P=0.004;28111participants,8trials).Heterogeneitywasabsent
(I
2=0%; P=0.70). Figure 6⇓ shows the forest plot.
Subgroupanalysesofthetrialsaccordingtolowriskofbiasdid
not change the effect estimates. Meta-analysis of trials with a
high risk of bias changed the effect estimate to a statistically
non-significant value (relative risk 0.83, 0.23 to 2.98; P=0.78;
306 participants, 3 trials). A test for interaction showed no
statistically significant difference in the effect estimates. We
couldnotdothesubgroupanalysesforlanguageofpublication,
durationofintervention,fundingsource,anddiagnosticcriteria
owing to lack of data.
Trial sequential analysis showed a lack of sufficient evidence
of a benefit of targeting intensive glycaemic control for the
reduction of non-fatal myocardial infarction (trial sequential
analysis adjusted 95% confidence interval 0.71 to 1.02). Only
27958(44%)oftheheterogeneityadjustedrequiredinformation
size of 63 446 patients required to detect a 10% relative risk
reduction for non-fatal myocardial infarction were accrued (fig
7⇓).
Composite outcome of microvascular
complications
We assessed a composite outcome of microvascular
complications, consisting of manifestation and progression of
nephropathy, end stage renal disease, manifestation and
progression of retinopathy, and retinal photocoagulation. We
could extract usable data from three trials that had a predefined
composite microvascular outcome.
4 5 8 The definitions of the
reported composite outcome varied among the included trials
(web appendix 2).
Forthecompositeoutcomeofmicrovascularcomplications,we
found a benefit of targeting intensive glycaemic control
compared with targeting conventional glycaemic control
(relative risk 0.88, 0.79 to 0.97; P=0.01; 25 600 participants, 3
trials) (fig 8⇓). The I
2 statistic was 45% (P=0.16). We found an
absoluteriskreductionofabout1%(riskdifference−0.01,95%
confidence interval −0.02 to 0.00; P=0.006). However, trial
sequential analysis did not show sufficient evidence for a 10%
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RESEARCHrelative risk reduction for the composite outcome of
microvascular complications (trial sequential analysis adjusted
95% confidence interval 0.76 to 1.01) (fig 9⇓).
Retinopathy
Retinopathy was primarily reported with the Early Treatment
of Diabetic Retinopathy Study (ETDRS) scale (web appendix
3). The effect estimate showed significant benefit in favour of
intensive glycaemic control (relative risk 0.80, 0.67 to 0.94;
P=0.009; 10 793 participants, 7 trials) (fig 10⇓). Heterogeneity
was substantial (I
2=59%; P=0.02). Trial sequential analysis
showedalackofsufficientevidencefora10%orgreaterrelative
risk reduction in retinopathy (trial sequential analysis adjusted
95% confidence interval 0.54 to 1.17) (fig 11⇓).
Nephropathy
Thedefinitionofnephropathyvariedamongtrials(webappendix
3). We found no statistically significant effect of intensive
glycaemic control on nephropathy (relative risk 0.83, 0.64 to
1.06; P=0.13; 27 769 participants, 8 trials) (fig 12⇓).
Heterogeneity was substantial (I
2=75%, P<0.001).
Severe hypoglycaemia
The definition of severe hypoglycaemia varied among trials
(web appendix 3). The ACCORD trial reported the number of
hypoglycaemic events in two ways—requiring any assistance
andrequiringmedicalassistance.Wehavereportedthenumber
requiringanyassistance,asthisdefinitionaccordsbestwiththe
definition in the other included trials.
5 Five trials, besides the
ACCORD trial, had the assistance of a third person as a part of
their definition of serious hypoglycaemia.
5 7 8 80 109
Meta-analysis of intensive versus conventional control showed
a statistically significant estimate of effect on severe
hypoglycaemia (relative risk 2.39, 1.71 to 3.34; P<0.001; 27
844 participants, 9 trials). Heterogeneity was substantial
(I
2=73%, P=0.005) (fig 13⇓).
For the application of trial sequential analysis to severe
hypoglycaemia, the protocol assumed an increase in relative
risk of 30%, equivalent to a number needed to harm of 50, to
construct the trial sequential monitoring boundaries. The
cumulative Z curve crossed the trial sequential monitoring
boundaryforharm,indicatingthatsufficientevidenceexistsfor
a 30% increase in relative risk of severe hypoglycaemia when
intensive glycaemic control is targeted (fig 14⇓).
Discussion
Our key finding is that whether the clinician is targeting an
intensive or conventional glycaemic value does not seem to
changetheriskofallcausemortalityorcardiovascularmortality.
However, intensive glycaemic control might reduce the risk of
non-fatal myocardial infarction, microvascular complications
(on the basis of a composite outcome), and retinopathy. The
riskofnephropathydoesnotseemtochangewiththeglycaemic
target. The price of intensive glycaemic control is an increased
risk of severe hypoglycaemia. However, among these
conclusions, only that for hypoglycaemia seems to be based on
a sufficient information size at this stage. A reduced risk of
microvascular disease with intensive versus conventional
glucose control has been found in several individual trials and
is consistent with findings in patients with type 1 diabetes.
However,ourmeta-analysissuggeststhatdataonmicrovascular
outcomes in patients with type 2 diabetes are still insufficient.
Absence of evidence cannot be taken as evidence of absence,
however, and an effect at the size of the point estimates found
in our meta-analyses may eventually be shown when further
trials are done.
112
Strengths and limitations
Thisisthefirstandmostcomprehensivesystematicreviewwith
meta-analyses of targeting intensive versus conventional
glycaemic control in patients with type 2 diabetes that focuses
on mortality and macrovascular as well as microvascular
complications. The strengths of this review are a published
protocol, a comprehensive search strategy, and rigid inclusion
criteria for the randomised trials.
13
We have included trials with large differences in the average
durationoftype2diabetes,lengthoftheinterventions,patients’
age and risk of cardiovascular disease, and assessment of
glycaemiccontrol,aswellaspre-specifiedtargetsofglycaemic
control. We included trials irrespective of the language of
publicationandoutcomesreported.Twoauthorsindependently
extracted data and obtained data from or confirmed data with
corresponding authors of the included trials.
Several meta-analyses have recently been published on this
topic.
113-121 However, many of the meta-analyses claiming to
assesstheeffectoftargetingintensiveglycaemiccontrolversus
conventionalglycaemiccontrolhaveincludedtrialsonthebasis
of achieved (that is, during follow-up) rather than targeted (that
is, as randomly allocated) differences in glycaemic
control.
113 115 116 120 121 For example, they included head to head
comparisonsofanti-diabetesdrugswithasimilartargetofHbA1c
below 6.5% in both intervention groups, such as the
PROspective pioglitAzone Clinical Trial In macroVascular
Events(PROactive)trialofadd-onpioglitazoneversusplacebo.
50
Boussageon et al applied the same approach in a recently
published meta-analysis.
113 This chosen strategy of selection is
potentially problematic, as the levels of glycaemic control
targetedandachievedinaclinicaltrialrepresentdifferentchosen
variables. To some extent, the achieved glycaemic control
represents observational data precluding inferences about
causality with respect to its influence on other outcomes. In
contrast, target levels, as part of the randomised intervention
strategy, can support inferences about causality. Therefore, to
optimally assess the clinical effect of aiming for intensive
glycaemic control, which is probably the relevant question for
theclinicianaswellaspeopletryingtoestablishevidencebased
guidelines, trials need to be meta-analysed primarily on the
basis of predefined differences in glycaemic targets.
The previous meta-analyses that dealt exclusively with trials in
which the patients were randomised to different glycaemic
targets included only four to six trials.
114 117-119 We included 14
trials, which is at least eight more trials than in the previous
meta-analysis. All of the meta-analyses investigating the effect
of targeting intensive glycaemic control have included the four
major trials,
4 5 6 8 which contributed the greatest number of the
participants in our analysis (27 391 of 28 614 participants).
However, none of the previous meta-analyses included trials
published in languages other than English or tested for the risk
of having false positive P values or unrealistically narrow
confidence intervals. Furthermore, none of the previous
meta-analyses was done as a Cochrane systematic review.
15
The weaknesses of our analyses and conclusions mirror the
weaknesses in the individual included trials. Most importantly,
only six of the 14 trials included were classified as trials with
alowriskofbias.However,wefoundnostatisticallysignificant
association between the risk of bias and the effect estimates in
subgroup analyses. Analysing cardiovascular mortality by
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RESEARCHdiagnostic criteria suggested a negative effect estimate for
intensive versus conventional glycaemic control in the trials
with a clear description of the diagnosis. However, analysis of
trials describing diagnostic criteria excluded the ADVANCE
trial, which is the largest trial included in this systematic review
(11 140 participants, about one third of the total information
size). Excluding the ADVANCE trial, which reported a neutral
effect of intensive versus conventional glycaemic control on
cardiovascular mortality, substantially increased the weight of
some other trials in the analysis. This applies in particular to
the ACCORD trial, which included a marginally lower number
of participants than did the ADVANCE trial. Unlike the
ADVANCE trial, the ACCORD trial reported an increased risk
of cardiovascular death for targeting intensive versus
conventionalglycaemiccontrol.Apartfromdiagnosticcriteria,
subgroupanalysesforothervariablessupportedtheconclusions
fromtheprimaryoverallanalysis.Giventhesomewhatarbitrary
criteriafortype2diabetes,theprogressivenatureofthedisease,
and, perhaps in particular, the inclusion of trials in this analysis
with different glycaemic targets and clinical outcomes, we find
it most likely that the reduced cardiovascular mortality with
conventional glycaemic control of the subgroup analysis
according to diagnostic criteria represents a chance finding,
possibly arising from confounding by the ACCORD trial.
We evaluated the strength of the available evidence by
comprehensiveanalysesoftheriskofsparsedataandrepetitive
testing with trial sequential analysis. We did this for outcomes
that showed significance in the cumulative meta-analysis,
calculating heterogeneity adjusted required information sizes
and applying trial sequential monitoring boundaries of benefit,
harm, and futility.
26 27 The result of the trial sequential analysis
rules out an effect of intensive glycaemic control on all cause
mortality larger than a 10% reduction in relative risk. Even
thoughtheconventionalmeta-analysesofnon-fatalmyocardial
infarction, composite microvascular complications, and
retinopathy indicated a statistically significant effect estimate,
trial sequential analysis showed that sufficient evidence was
not yet available for a conclusion to be reached.
In addition to the differences between the glycaemic targets
among the trials, the conventional treatment groups as well as
the anti-diabetes interventions used to achieve the targets
differed among the trials. Furthermore, the measurement used
to assess the levels of glycaemic control varied among the
included trials. Some trials defined the target glucose values by
using blood glucose, providing only a “snapshot” of the overall
glycaemic control. Most of the included trials expressed
glycaemic control and glycaemic targets in values of HbA1c,
reflecting an average of the blood glucose concentration over
several weeks. We were unable to evaluate the effects of the
specific anti-diabetes drugs used to achieve the glycaemic
targets. A wide range of glucose lowering interventions were
used to achieve the glycaemic goal within and among the trials.
IntheACCORDandtheADVANCEtrials,agreaterproportion
of the participants randomised to intensive glycaemic control
receivedrosiglitazonecomparedwiththeconventionaltreatment
group.
4 5 We have not been able to quantify any drug specific
effects on our outcomes that may counteract or contribute to
bothbenefitsandharmsofglycaemiccontrol.Themostsuitable
way to answer the specific question of whether the target in
itselfaffectsoutcomesimportanttopatientswouldbetoinclude
onlytrialsthatusedonebloodglucoseloweringdrugexclusively
toreceiveapredefinedglycaemictarget.However,suchadesign
would seem to be inapplicable to clinical practice.
The participants in the included trials represented a diverse
populationwithtype2diabetes.Theresultsofourreviewshould
beinterpretedwiththisinmind.Thediagnosisoftype2diabetes
variedamongthetrials,andsometrialsusedadefinitionoftype
2 diabetes that may have included participants with impaired
glucose tolerance. Some of the trials included only participants
with newly diagnosed type 2 diabetes, whereas others included
patients with longer duration of type 2 diabetes. Participants’
age, body mass index, glycaemic control, and duration of
diabeteswereinkeepingwithwhatmightbeexpectedinclinical
practice. In spite of this, for several effects of the intervention
on outcomes, we found no or only moderate heterogeneity.
Furthermore, we found no significant subgroup differences
when we stratified for the diagnostic criteria used for inclusion
inthetrials.Althoughweincludedabroadspectrumofpatients
with type 2 diabetes and, owing to potential selection bias—for
instance, towards healthier and more motivated patients
volunteering in a clinical trial compared with the background
population of patients—saying how typical the participants in
each clinical trial may be compared with the wider general
population of patients with type 2 diabetes is difficult. On the
otherhand,theheterogeneityinthisreviewmightindeedreflect
the well known heterogeneity in clinical practice.
Thereportingofseverehypoglycaemiaisproblematicinseveral
ways; first of all, the definitions of severe hypoglycaemia were
diverse. Many of the trials included assistance from another
person, without further specification. The grade of assistance
from another person may vary from handing a juice to giving
glucagoninjections.Inaddition,thedesignoftheincludedtrials
made blinding the participants impossible, which may in turn
lead to reporting bias.
15
Many of the included trials were not designed or powered to
assessourpredefinedoutcomes,whichexplainstheinsufficient
data from these trials. Furthermore, for some outcomes only a
fewtrialscouldprovidedata.Thisincreasestheriskofoutcome
measure reporting bias.
15
Relation to other studies and reviews
The UGDP was the first “large scale,” multicentre clinical trial
on the topic. It did not find any differences in mortality and
cardiovascular outcomes between targeting intensive or
conventional glycaemic control with insulin.
88 The much larger
UKPDS also failed to show a benefit on mortality or
cardiovascular outcomes for targeting intensive glycaemic
control with insulin or a sulfonylurea.
8 However, a small
subgroup of 753 overweight patients randomly assigned to
intensive glycaemic control with metformin showed a benefit
of intensive glycaemic control.
100 Post hoc observational data
fromtheUKPDSsuggestedthata1%decreaseinHbA1creduced
the risk of non-fatal myocardial infarction by 14%.
1 A 10 year
follow-up of the initial randomised groups in the UKPDS
suggested long term beneficial effects of intensive glucose
control on cardiovascular disease and mortality with both
metformin and sulfonylurea-insulin regimens. Our analysis
indicatedasignificant15%reductioninrelativeriskofnon-fatal
myocardial infarction in favour of intensive glycaemic control.
However, this was not confirmed when challenged for a 10%
relativeriskreductionintrialsequentialanalysiswithadjustment
for repetitive testing on accumulating and sparse data. A
potential explanation for the magnitude of beneficial effects of
lower glucose concentrations being more pronounced in
observational studies than in randomised trials and prospective
studies is the effects of confounding by indication in the
observational studies.
Recently, two large trials attempted to answer the question of
whetherintensiveglycaemiccontrolissuperiortoconventional
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4 5 Worries arose as the results from the
ACCORD trial in 2008 showed increased all cause mortality
and cardiovascular mortality with intensive glycaemic control
compared with conventional glycaemic control. The increased
mortality led to early termination of the ACCORD trial. On the
other hand, the ACCORD trial showed a reduction in the risk
of non-fatal myocardial infarction with intensive glycaemic
control. The question remains why the ACCORD trial reported
increased mortality but a reduced risk of non-fatal myocardial
infarction. Recently, data from the follow-up period, after
termination of the intensive glycaemic intervention arm, have
been published and reported that the increased risk of mortality
and reduced risk of non-fatal myocardial infarction have
persisted.
122 Explanations for this finding have been sought by
theauthorsoftheACCORDtrial,butnofirmevidencehasbeen
found.
Observational data from the UKPDS showed a 37% reduction
intheriskofmicrovascularcomplicationsforeach1%decrease
in HbA1c.
1 The ADVANCE trial found a 14% relative risk
reduction for major microvascular events when targeting
intensive glycaemic control.
75 The UKPDS 33 showed a 25%
risk reduction in microvascular outcomes when targeting
intensive glycaemic control.
8 We found a 12% relative risk
reduction for the composite microvascular outcome. We found
a 20% relative risk reduction for retinopathy in favour of
intensive glycaemic control. The absolute risk reduction was
3%.
The Kumamoto trial showed a pronounced reduction in the
incidenceofnephropathyinboththeprimarypreventioncohort
(11.5% v 43.5%) and the secondary intervention cohort (16%
v 40%) when targeting intensive glycaemic control.
7 The
ADVANCE trial showed a 21% relative risk reduction for
nephropathy when targeting intensive glycaemic control,
whereas this could not be shown in ACCORD.
5 74 We found no
significant effect of glycaemic intervention on the risk of
nephropathy.
Microvascular data from the ACCORD trial and the UKPDS
indicatethatthebeneficialeffectsofintensiveglycaemiccontrol
on microvascular disease take more than about five years to
emerge or that the benefits on microvascular disease achieved
by intensive glycaemic control are less pronounced for patients
with advanced type 2 diabetes (ACCORD) than for patients
with new onset of type 2 diabetes (UKPDS).
8 74 On the other
hand, the meta-analysis of retinopathy indicated that patients
with more advanced stages of type 2 diabetes (ACCORD,
VADT) might benefit more from intensive glycaemic control
than do patients newly diagnosed as having type 2 diabetes
(UKPDS, UGDP).
6 8 74 91
We identified severe hypoglycaemia as a serious adverse effect
stronglyassociatedwithintensiveglucosecontrol,whichseems
to be in accordance with established knowledge and other
meta-analyses.
114 116 117 We did not have access to trial data at
the level of the patient, so we could not explore whether an
association exists between severe hypoglycaemic events and
the risk of sudden unexpected death.
In January 2010 the American Diabetes Association published
a guideline recommending an HbA1c goal of less than 7% to
reduce microvascular complications.
10 Treatment targets of
HbA1c at 7% have been used in only three trials exclusively
dealing with glycaemic control in usual care setting, and they
are all of relatively small sample size, consisting in total of 234
participants.
7 82 85 Only one of these trials had a duration of more
than one year.
7
Conclusion
We found evidence to refute the suggestion that intensive
comparedwithconventionalglycaemiccontrolreducesallcause
mortality with a relative risk reduction of 10% or more. We
found insufficient information to confirm or exclude a 10%
relativeriskreductionincardiovascularmortalityandnon-fatal
myocardial infarction with intensive glycaemic control. We
found insufficient evidence for a reduction in risk of composite
microvascular complications, retinopathy, and nephropathy.
Conversely, we confirmed a 30% increase in relative risk of
severe hypoglycaemia with intensive compared with
conventional glycaemic control. Accordingly, treatment and
choice of a glycaemic target for patients with type 2 diabetes
need to take both harms and benefits into account.
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RESEARCHWhat is already known on this topic
Patients with type 2 diabetes are at increased risk of macrovascular and microvascular disease
Uncertainty exists as to whether intensive glycaemic control reduces the risk of death, macrovascular disease, or microvascular disease
Only a few meta-analyses with a high risk of bias have estimated the effect of intensive glycaemic control on microvascular complications
What this study adds
Sufficient evidence exists for an absence of a 10% relative risk reduction in all cause mortality with intensive glycaemic control versus
conventional glycaemic control in patients with type 2 diabetes
Insufficient evidence exists for a 10% relative risk reduction in cardiovascular mortality and non-fatal myocardial infarction
Insufficient evidence exists to support the conclusions that intensive glycaemic control prevents the occurrence of microvascular disease
assessed as a composite outcome, retinopathy, or nephropathy
Sufficient evidence exists that intensive glycaemic control increases the risk of severe hypoglycaemia by 30% compared with conventional
glycaemic control
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RESEARCHTables
Table 1| Excluded trials
Reason for exclusion Trial
No predefined differences in glycaemic target ADOPT 2010
46
Did not include participants with type 2 diabetes Barbosa et al 1983
42
No predefined differences in glycaemic target BARI 2D 2009
47
Not a randomised clinical trial Barnett et al 2008
31
Patients with type 2 diabetes reported together with patients without diabetes Blaha et al 2009
43
Not a randomised clinical trial Brocco et al 2001
32
No predefined differences in glycaemic target Chan et al 2009
48
Not a randomised clinical trial Clark et al 1985
33
No predefined differences in glycaemic target Cleveringa et al 2010
49
Not a randomised clinical trial Corpus et al 2004
34
Patients with type 1 diabetes and type 2 diabetes reported together DIGAMI 1996
45
Intensive glycaemic control applied as a part of acute intervention DIGAMI 2 2005
19 65
No predefined differences in glycaemic target Du et al 2009
51
Not a randomised clinical trial Eastman et al 1997
35
Not a randomised clinical trial Eibl et al 2004
36
Not a randomised clinical trial Evans et al 1982
37
Not a randomised clinical trial Furnary et al 1999
38
Intensive glycaemic control applied as part of multimodal intervention Guo et al 2008
17
No predefined differences in glycaemic target Hanefeld et al 2010
52
Randomised into two groups targeting same HbA1c with different strategies (basal v prandial) HEART 2D 2009
59
No predefined differences in glycaemic target Johansen et al 2007
54
No predefined differences in glycaemic target Joss et al 2002
55
Patients with type 1 diabetes and type 2 diabetes reported together Lazar et al 2004
44
Not a randomised clinical trial Leibowitz et al 2010
41
Intensive glycaemic control applied as part of acute intervention Melidonis et al 2000
20
No predefined differences in glycaemic target Menard et al 2005
56
No predefined differences in glycaemic target Olivarius et al 2001
57
No predefined differences in glycaemic target Piatt et al 2010
58
No predefined differences in glycaemic target PROactive et al 2005
50
Not a randomised clinical trial Retnakaran et al 2010
39
Not a randomised clinical trial Ryan et al 2004
40
No predefined differences in glycaemic target Shi et al 2010
60
Intensive glycaemic control applied as part of acute intervention Stefanidis et al 2003
21 66
Intensive glycaemic control applied as part of multimodal intervention Steno 2 2008
16 62-64
No predefined differences in glycaemic target UKPDS-44 1999
53
No predefined differences in glycaemic target Van Bruggen et al 2009
61
Intensive glycaemic control applied as part of multimodal intervention Yang et al 2007
18
ADOPT=A Diabetes Outcome Progression Trial; BARI 2D=Bypass Angioplasty Revascularization Investigation 2 Diabetes; DIGAMI=Diabetes Insulin-Glucose in
Acute Myocardial Infarction; HbA1c=glycated haemoglobin A1c; HEART 2D=Hyperglycaemia and Its Effect After Acute Myocardial Infarction on Cardiovascular
Outcomes in Patients With Type 2 Diabetes Mellitus; PROactive=PROspective pioglitAzone Clinical Trial In macroVascular Events; UKPDS=United Kingdom
Prospective Diabetes Study.
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RESEARCHTable 2| Key characteristics of included trials
Conventional glycaemic
control Intensive glycaemic control
Length of
follow-up*
No of
intensive/conventional
(total) participants Design Location Trial
HbA1c 7.0-7.9%; fasting SMBG
>5.0 mmol/L
HbA1c <6%; fasting SMBG <5.6
mmol/L or 2 hour blood glucose <7.8
mmol/L
3.5 years 5128/5123 (10 251) Randomised,
2×2 factorial
design
77 centres; USA
and Canada
ACCORD
2008
4 67-74
Glycaemic target of HbA1c
defined from local guidelines
HbA1c ≤6.5% 5.0 years 5571/5569 (11 140) Randomised,
factorial design
215 centres; 20
countries
ADVANCE
2008
75-78
Avoid symptoms of
hyperglycaemia and fortnightly
fasting capillary glucose test
>17 mmol/L
HbA1c <7%; before meal capillary
glucose 4-7 mmol/L; 2 hour blood
glucose <10 mmol/L
20 weeks 21/22 (43) Randomised 1 centre; New
Zealand
Bagg et al
2001
79-82
Fasting capillary blood glucose
<8.5 mmol/L
Fasting capillary blood glucose <6.5
mmol/L
22 months 106/108 (231) Randomised 1 centre;
Netherlands
Becker et al
2003
83 84
Standard treatment HbA1c <6.5%; fasting blood glucose
5-7 mmol/L; before meal <10
mmol/L
6 months and 3
weeks
51/51 (102) Randomised 2 centres;
Sweden
IDA 2009
92 93
Not defined Fasting blood glucose ≤6.6 mmol/L;
2 hour postprandial glucose <10
mmol/L, or to reach maximum daily
dose of sulfonylurea
4 months 23/22 (45) Randomised 1 centre; USA Jaber et al
1996
94
Fasting blood glucose close to
<140 mg/dL without symptoms
of hyperglycaemia or
hypoglycaemia
HbA1c <7.0%; fasting blood glucose
<140 mg/dL; 2 hour postprandial
glucose <200 mg/dL; mean
amplitude of glycaemic excursions
<100 mg/dL
10 years 55/55 (110) Randomised 1 centre; Japan Kumamoto
2000
7 95 96
Fasting blood glucose <7.0
mmol/L; postprandial 2 hour
glucose <10.0 mmol/L
Fasting blood glucose <6.1 mmol/L,
postprandial 2 hour glucose <7.8
mmol/L
12 weeks 21/20 (41) Randomised 1 centre; China Lu et al 2010
86
Not specified HbA1c <7% in participants receiving
sulfonylurea; HbA1c <6.5% in
participants receiving insulin
12 months 41/40 (81) Randomised 1 centre; Russia REMBO 2008
85
Eliminate symptoms, but not
to degree to reduce 80 minute
postprandial plasma glucose
below 150 mg/dL
HbA1c to normal range, and to
maintain 80 minute postprandial
plasma glucose <8.3 mmol/L
1.75 years 10/10 (20) Randomised 1 centre; USA Service et al
1983
87
Minimise likelihood of
hypoglycaemic reactions
without reducing insulin dose
to pharmacologically inactive
amounts
Maintain blood glucose in normal
range (defined as fasting blood
glucose <110 mg/100 mL, blood
glucose <210 mg/100 mL 1 hour
after ingestion of 50 g glucose and
1 and 1.5 hours after morning insulin
injection)
12 years 204/210 (414) Randomised 12 centres; USA UGDP 1978
88-91
Fasting blood glucose <15
mmol/L without symptoms of
hyperglycaemia
Fasting blood glucose <6 mmol/L in
insulin treated patients; pre-meal
glucose 4-7 mmol/L
UKPDS 33
10.0 years;
UKPDS 34
10.7 years
3071/1138 (4209) Randomised
(some
participants
randomised to
blood pressure
arm)
23 centres, UK UKPDS 1998
1 8
97-102
Avoid excessive
hyperglycaemia or symptoms
of excessive glucosuria,
ketonuria, or hypoglycaemia
(alert HbA1c <12.9%)
Maintain mean HbA1c <7.5%;
treatment adjusted with home blood
glucose monitoring, aiming at fasting
blood glucose 4.48-6.44 mmol/L and
other pre-prandial levels ≤7.28
mmol/L
27 months 75/78 (153) Randomised 5 centres; USA VA CSDM
1995
103-109
Wellbeing, avoidance of
deterioration of HbA1c, keeping
levels at 8-9%, and preventing
symptoms of glycosuria,
hypoglycaemia, and ketonuria
HbA1c ≤6%; goal for HbA1c was
absolute reduction of 1.5 percentage
points in intensive therapy group,
compared with conventional
intervention group
5.6 years 892/899 (1791) Randomised 20 centres; USA VADT 2009
6 110
111
ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled
Evaluation; HbA1c=glycated haemoglobin A1c; IDA=Insulin Diabetes Angioplasty; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against
DiaBetes Mellitus in Patients With COngestve Heart Failure; SMBG=self monitoring of blood glucose; UGDP=University Group Diabetes Program; UKPDS=United
Kingdom Prospective Diabetes Study; VACSDM=Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.
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RESEARCHTable 2 (continued)
Conventional glycaemic
control Intensive glycaemic control
Length of
follow-up*
No of
intensive/conventional
(total) participants Design Location Trial
*Mean or median.
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RESEARCHTable 3| Key characteristics of participants
Previous cardiovascular
disease,
Fasting blood glucose
at baseline (mmol/L)*† HbA1c at baseline (%)*
Duration of disease at
baseline (years)* Age (years)* Trial
intensive/conventional
(No)
1826/1783 9.8 8.3 10 62.2 ACCORD 2008
4 67-74
1794/1796 8.5 7.5 8.0 66.0 ADVANCE 2008
75-78
2/2 13.5 10.7 6.9 55.9 Bagg et al 2001
79-82
21/23 9.6 NR 3.3 63.3 Becker et al 2003
83 84
51/51 7.2 6.5 6.5 64.0 IDA 2009
92 93
NR 12.0 11.9‡ 6.5 62.4 Jaber et al 1996
94
0/0 9.2 9.2 8.6 49.6 Kumamoto 2000
7 95 96
NR 9.3 9.0 8.2 59.5 Lu et al 2010
86
41/40 6.6 7.2 5.5 64 REMBO 2008
85
NR 8.7 11.4 0.5 50.7 Service et al 1983
87
7/16¶ 7.9 NR Newly diagnosed 52.7§ UGDP 1978
88-91
77†† 8.1** 7.1** Newly diagnosed 53.2** UKPDS 1998
1 8 97-102
31/27 11.9 9.4 7.8 60.1 VA CSDM 1995
103-109
355/368 10.9 9.4 11.5 60.4 VADT 2009
6 110 111
ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled
Evaluation; IDA=Insulin Diabetes Angioplasty; NR=not reported; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against DiaBetes Mellitus
in Patients With COngestve Heart Failure; UGDP=University Group Diabetes Program; UKPDS=United Kingdom Prospective Diabetes Study; VACSDM=Veterans
Affairs Cooperative Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.
*Mean or median.
†Converted from mg/dL to mmol/L by dividing by 18.
‡Described as glycated haemoglobin.
§Age reported for all treatment groups together.
¶Previous cardiovascular disease reported as history of angina.
**Number for baseline characteristics taken from UKPDS 33.
††Number taken from meta-analysis by Turnbull et al.
114
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RESEARCHTable 4| Risk of bias assessments of included trials
Free from other bias
Selective outcome
reporting
Incomplete outcome
data Blinding
Allocation
concealment
Sequence
generation Trial
Inadequate Adequate Unclear Adequate Adequate Adequate ACCORD 2008
4 67-74
Inadequate Adequate Adequate Adequate Adequate Adequate ADVANCE 2008
75-78
Adequate Adequate Adequate Adequate Unclear Unclear Bagg et al 2001
79-82
Adequate Adequate Unclear Unclear Unclear Unclear Becker et al 2003
83 84
Inadequate Adequate Adequate Adequate Adequate Adequate IDA 2009
92 93
Inadequate Adequate Adequate Unclear Unclear Unclear Jaber et al 1996
94
Inadequate Unclear Adequate Unclear Unclear Unclear Kumamoto 2000
7 95 96
Adequate Adequate Unclear Unclear Unclear Unclear Lu et al 2010
86
Unclear Adequate Adequate Unclear Unclear Unclear REMBO 2008
85
Adequate Adequate Adequate Adequate Unclear Adequate Service et al 1983
87
Adequate Adequate Adequate Adequate Adequate Adequate UGDP 1978
88-91
Inadequate Adequate Adequate Adequate Adequate Adequate UKPDS 1998
1 8 97-102
Inadequate Adequate Adequate Adequate Unclear Unclear VA CSDM 1995
103-109
Inadequate Adequate Adequate Adequate Adequate Adequate VADT 2009
6 110 111
ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled
Evaluation; IDA=Insulin Diabetes Angioplasty; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against DiaBetes Mellitus in Patients With
COngestve Heart Failure; UGDP=University Group Diabetes Program; UKPDS=United Kingdom Prospective Diabetes Study; VACSDM=Veterans Affairs Cooperative
Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.
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RESEARCHFigures
Fig 1 Flow diagram of identification of randomised trials for inclusion
Fig 2 Forest plot for all cause mortality
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RESEARCHFig 3 Trial sequential analysis of all cause mortality. Heterogeneity adjusted required information size of 46 677 participants
calculated on basis of proportion of mortality of 8.4% in conventional glucose control group, relative risk reduction of 10%,
α=5%, β=20%, and I
2=30%. Actually accrued No of participants was 28 149, 60% of required information size. Dashed red
cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm, but boundaries for
futility (blue inner wedge boundaries) are crossed. Horizontal dotted green lines illustrate traditional level of statistical
significance (P=0.05)
Fig 4 Forest plot for cardiovascular mortality
Fig 5 Trial sequential analysis for cardiovascular mortality. Heterogeneity adjusted required information size of 129 468
participants calculated on basis of proportion of cardiovascular mortality of 4.1% in conventional glucose control group,
relative risk reduction of 10%, α=5%, a β=20%, and I
2=46%. Actually accrued No of participants was 28 149, 22% of required
information size. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit
or harm. Horizontal dotted green lines illustrate the traditional level of statistical significance (P=0.05)
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RESEARCHFig 6 Forest plot for non-fatal myocardial infarction
Fig 7 Trial sequential analysis for non-fatal myocardial infarction. Heterogeneity adjusted required information size of 63
446 participants calculated on basis of proportion of non-fatal myocardial infarction of 4.5% in conventional glucose control
group, relative risk reduction of 10%, α=5%, β=20%, and I
2=0%. Actually accrued No of participants was 27 958, 44% of
required information size. Dashed red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries
for benefit or harm. Horizontal dotted green lines illustrate the traditional level of statistical significance (P=0.05)
Fig 8 Forest plot for composite microvascular outcome
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RESEARCHFig 9 Trial sequential analysis for composite microvascular outcome. Heterogeneity corrected required information size of
43 703 participants calculated on basis of proportion of composite microvascular outcome of 11.1% in conventional glucose
control group, relative risk reduction of 10%, α=5%, β=20%, and I
2=45%. Dashed red cumulative Z curve does not cross
solid blue trial sequential monitoring boundaries for benefit or harm. Horizontal dotted green lines illustrate the traditional
level of statistical significance (P=0.05)
Fig 10 Forest plot for retinopathy
Fig 11 Trial sequential analysis for retinopathy. Heterogeneity corrected required information size of 43 960 participants
calculated on basis of proportion of retinopathy of 14.3% in conventional glucose control group, relative risk reduction of
10%, α=5%, β=20%, and I
2=59%. Actually accrued No of participants was 10 793, 25% of required information size. Dashed
red cumulative Z curve does not cross solid blue trial sequential monitoring boundaries for benefit or harm. Horizontal dotted
green lines illustrate the traditional level of statistical significance (P=0.05)
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RESEARCHFig 12 Forest plot for nephropathy
Fig 13 Forest plot for severe hypoglycaemia
Fig 14 Trial sequential analysis for severe hypoglycaemia. Heterogeneity adjusted required information size of 36 937
participants calculated on basis of proportion of severe hypoglycaemia of 2.9% in conventional glucose control group,
relative risk reduction of 30%, α=5%, β=20%, and I
2=73%. Cumulative Z curve crosses trial sequential monitoring boundary,
showing sufficient evidence reached for 30% increase in relative risk with targeted intensive glycaemic control. Horizontal
dotted green lines illustrate the traditional level of statistical significance (P=0.05)
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